ENGLISH OVERVIEW

TNP Newsletter

2018/5/16

197th Business Plan Presentations Held on May 8, 2018 at Iwasaki Gakuen, Shin-Yokohama, Japan

1. Malignant Tumor Treatment Technologies, Inc. President Mr. Toshiyasu Miyazaki

http://www.mt3.co.jp/blank024.html

Established in October 2017 Capital stock：USD＄ 10,000

Malignant Tumor Treatment Technologies, Inc. is a new drug developer pursuing practical utilization of sensitizers for anti-cancer radiotherapy. It has already become possible to synthesize, in massive quantities, sensitizers deriving from products in the natural world which were found to be completely free of cytotoxicity in non-clinical tests of safety based on Good Laboratory Practice (GLP) standards. The work also suggests the possibility of allowing a reduction in radiation doses. Favorable results have been obtained in use for naturally occurring cancer in dogs and cats at university veterinary hospitals. As official approval for use as a drug for animals is both definite and can be obtained earlier, the company is first taking aim at sales of the sensitizer as such a drug. At present, there are about eight facilities conducting radiotherapy for pets in Japan. Clinical trials are already being performed at two, and the company is beginning to contact the remaining ones. It plans to invest the earnings from sales of drugs for pets into activities for clinical trials of, and application for official approval for, pharmaceuticals for treatment of human patients. By these means, it intends to promote the development of new drug business that does not require the procurement of external funds in huge amounts.

【Re-Cap】 Currently, there are three basic types of treatment for cancer: 1) surgery, 2) chemotherapy, and 3) radiotherapy. Of these, radiotherapy is a localized treatment that focuses on the cancerous tissue and irradiates it with beams of radiation. It consequently is gentle to the body; the treatment per se is not painful, and side-effects can be held to a minimal level. It is impossible, however, to induce the maximum effect unless the irradiation is performed after raising the oxygen concentration at the center of the cancer tissue. This is behind the need for anti-cancer radiotherapy sensitizers.

2. Ad Me Tech Co.,Ltd. President Mr. Shinichi Nakazumi http://www.admetech.co.jp/(Japanese)

Established in September 2003 Capital stock：USD＄ 2,200,000

Ad Me Tech Co., Ltd. is a venture that originated in Ehime University and rests on partnership between academia and industry. It uses heat to fight malignant tumors that cannot be treated by surgery or radiation. It has already obtained official approval for its equipment as a type of medical apparatus directed to veterinary hospitals. About 160 units are already in operation in Japan.

At present, the company is developing instruments and devices for deep organs. These items were first officially approved for use last autumn in the Ukraine, where they have come into clinical application at the national cancer center. There, physicians insert the company's micro heat-generating needle and catheter into the affected part while confirming the location of the tumor by computer tomography and echo images, through a low-invasive procedure without laparotomy. The technology induces an irreversible thermal denaturation of the affected part in a both pin-point and safe manner, while controlling the temperature. Because the procedure is a physical one, the type of cancer does not matter as long as it is a variety of solid carcinoma. The genetic mutation of cancer cells also does not cause any problem.

For the future, the company plans to develop business in the technology as medical apparatus, beginning with countries outside Japan. In addition, through the joint research now under way with more than one university hospital in Japan, it wants to revive tissue affected by localized tumors, which has been difficult with treatment so far, and thereby help to lengthen and save the lives of cancer patients as well as better their quality of life.

【Re-Cap】 Ad Me Tech's technology constitutes a new type of therapy based on application of heat. It is an addition to the existing types and can also be used together with them. It can also be used in conjunction with cellular immunotherapy and antibody drugs (monoclonal antibodies) that have become a focus of attention in recent years. This therapy based on application of heat has few side effects, because it does not involve the administration of drugs or exposure to radiation. The pet medical apparatus now being sold heats affected parts under the skin to a temperature of 50 - 60 degrees centigrade for about 10 minutes, and the treatment can be completed in one session. The company is listed on the Tokyo Pro Market, and Mr. Nakazumi said he was taking aim at a higher listing further in the future.

3. Hotate Powder Co.,Inc. President Mr. Tai Tachibana http://www.hotatepowder.co.jp/hotatete.php



Established in December 2013 Capital stock：USD＄ 285,000

Shells from scallops have thus far been discarded as waste. Hotate Powder Co., Inc. pulverizes those from scallops produced in Aomori Prefecture and fires the resulting powder at a temperature of 1,100 degrees centigrade. It then adds water to turn it into calcium hydroxide, and utilizes the sterilizing and deodorizing capabilities of this substance to develop anti-bacterial agents, disinfectants, and deodorizers. It is also developing and selling cutting boards and other home articles made with it. The anti-bacterial agents containing calcium from fired scallop shells derive from a natural anti-bacterial constituent that is highly safe and also a food additive. They are strong enough for uses ranging from disinfection to treatment for bacteria related to food poisoning in hospitals, nursing facilities, catering centers, restaurants, and other such facilities. They can also handle spore-forming bacteria. Unlike alcohol disinfectants, they do not hurt the fingers. The company spent a period of about three years after its founding in research and development. It is in possession of all sorts of evidence (in Japanese and English, with photos) from third-party institutions. It has an additional advantage in the form of an agreement permitting use of a patent related to PE and calcium hydroxide owned by a related company.

- The cutting board has the highest level of anti-bacterial and heat resistance performance in Japan (a heat resistance to 110 degrees centigrade and anti-bacterial activity value in the range of 4.7 - 6.0). It has also been designated for use by large restaurant companies. In the summer of this year, it intends launch a new cutting board product as part of a global strategy, and to apply for a patent of its own at the same time.
- The company spent about three years in joint development (as it proceeded, the work attracted the participation of two companies listed on the First Section of the Tokyo Stock Exchange) of an anti-bacterial non-woven fabric. Its schedule envisions introduction to the mass media around October 2018 and launch of sales by the end of the year.
- The company is currently developing a sodium hypochlorite disinfection system with a large firm dealing in cut vegetables, for use in sterilization and disinfection in advance of product shipment from the plant.

【Re-Cap】 There are many products in the market that are presented as "anti-bacterial," but in reality, consumers probably are not sure of their actual effectiveness, which is not apparent to the eye. In addition, because the products may be used on a daily basis, it is extremely important that they they do not chap the skin. In his presentation, Mr. Tachibana brought along some litmus paper and demonstrated the effectiveness of his product in a visible manner. As a result, all participants were able to get good idea of its unmistakeable effect.

《Impressions》 Reflecting the high degree of interest in it, this last meeting drew numerous participants and spurred lively discussion among them. We earnestly hope that the presentations will be linked to further business opportunities for the firms which made them.We ask any companies that would like to make presentations at the meeting to please contact us early.

NPO Venture Support Mechanism MINERVA
TNP Partners / TNP On The Road